Table 2

UCSF trials: comparisons of baseline characteristics

VariableTrial 1
N=149
Trial 2
N=199
Trial 3
N=219
Trial 4
N=160
Significance*Effect size*Significance†Effect size†
M (SD)M (SD)M (SD)M (SD)
Cigarettes per day24.9 (10.8)22.5 (9.8)21.4 (9.0)19.2 (7.2)F(3, 723)=10.4, p<0.0010.04esF(3, 712)=9.63, p<0.0010.04es
Nicotine dependence‡6.4 (1.9)5.5 (2.1)4.8 (2.2)4.6 (2.0)F(3, 709)=24.0, p<0.0010.09esF(3, 699)=22.67, p<0.0010.09es
Current depressive symptoms§5.1 (5.1)8.9 (7.0)8.1 (7.2)8.4 (7.3)F(3, 716)=9.7, p<0.0010.04esF(3, 706)=9.65, p<0.0010.04es
Age40.6 (9.2)40.7 (9.6)39.4 (11.3)38.6 (10.0)F(3, 719)=1.8, p=0.150.01es
Body mass index24.4 (3.8)24.9 (3.6)24.9 (4.5)F(2, 526)=0.8, p=0.460.00
% Female52.355.344.341.3χ2(3)=9.5
p=0.02
0.11v
% Partnered38.341.633.846.5χ2(3)=6.7
p=0.08
0.10v
% Minority12.112.217.822.5χ2(3)=9.3
p=0.03
0.11v
% College degree59.753.354.6χ2(2)=1.5
p=0.46
0.05v
  • *0.01 small, 0.06 medium and 0.14 large; Partial η2: 0.04 recommended minimum effect size; Cramer's V: 0.2 recommended minimum effect size.

  • †Significance after controlling for sex, age and minority status.

  • ‡Nicotine dependence was self-reported using the Fagerström Test for Cigarette Dependence34

  • §Current depressive symptoms were self-reported using the Beck Depression Inventory (BDI-II).

  • ¶Partnered refers to participants who reported that they had a live-in partner.

  • es, η2; v, Cramer's V.